This study aimed to investigate the anti-fibrotic effects of ghrelin in isoproterenol (ISO)-induced myocardial fibrosis and the underlying mechanism. Sprague-Dawley rats were randomized to control, ISO, and ISO + ghrelin groups. ISO (2 mg/kg per day, subcutaneous) or vehicle was administered once daily for 7 days, then ghrelin (100 microg/kg per day, subcutaneous) was administered once daily for the next 3 weeks. Ghrelin treatment greatly improved the cardiac function of ISO-treated rats. Ghrelin also decreased plasma brain natriuretic peptide level and ratios of heart weight to body weight and left ventricular weight to body weight. Ghrelin significantly reduced myocardial collagen area and hydroxyproline content, accompanied by decreased mRNA levels of collagen type I and III. Furthermore, ghrelin increased plasma level of growth differentiation factor 15 (GDF15) and GDF15 mRNA and protein levels in heart tissues, which were significantly decreased with ISO alone. The phosphorylation of Akt at Ser473 and GSK-3beta at Ser9 was decreased with ISO, and ghrelin significantly reversed the downregulation of p-Akt and p-GSK-3beta. Mediated by GDF15, ghrelin could attenuate ISO-induced myocardial fibrosis via Akt-GSK-3beta signaling.

Geriatric Department of the 3rd Hospital of Hangzhou Hangzhou China

Zobrazit více v PubMed

ANAND IS, KEMPH T, RECTOR TS, TAPKEN H, ALLHOFF T, JANTZEN F, KUSKOWSKI M, COHN JN, DREXLER H, WOLLERT KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387–1395. doi: 10.1161/CIRCULATIONAHA.109.928846. PubMed DOI

BALDANZI G, FILIGHEDDU N, CUTRUPI S, CATAPANO F, BONISSONI S, FUBINI A, MALAN D, BAJ G, GRANATA R, BROGLIO F, PAPOTTI M, SURICO N, BUSSOLINO F, ISGAARD J, DEGHENGHI R, SINIGAGLIA F, PRAT M, MUCCIOLI G, GHIGO E, GRAZIANI A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002;159:1029–1037. doi: 10.1083/jcb.200207165. PubMed DOI PMC

CAMARGO-SILVA G, TURONES LC, Da CRUZ KR, GOMES KP, MENDONCA MM, NUNES A, De JESUS IG, COLUGNATI DB, PANSANI AP, POBBE RLH, SANTOS R, FONTES MAP, GUATINOSIM S, De CASTRO CH, IANZER D, FERREIRA RN, XAVIER CH. Ghrelin potentiates cardiac reactivity to stress by modulating sympathetic control and beta-adrenergic response. Life Sci. 2018;196:84–92. doi: 10.1016/j.lfs.2018.01.019. PubMed DOI

CHUNG H, LI E, KIM Y, KIM S, PARK S. Multiple signaling pathways mediate ghrelin-induced proliferation of hippocampal neural stem cells. J Endocrinol. 2013;218:49–59. doi: 10.1530/JOE-13-0045. PubMed DOI

CIESZKOWSKI J, WARZECHA Z, CERANOWICZ P, CERANOWICZ D, KUSNIERZ-CABALA B, PEDZIWIATR M, DEMBINSKI M, AMBROZY T, KACZMARZYK T, PIHUT M, WIECKIEWICZ M, OLSZANECKI R, DEMBINSKI A. Therapeutic effect of exogenous ghrelin in the healing of gingival ulcers is mediated by the release of endogenous growth hormone and insulin-like growth factor-1. J Physiol Pharmacol. 2017;68:609–617. PubMed

EID RA, ALKHATEEB MA, ELEAWA S, AL-HASHEM FH, AL-SHRAIM M, EL-KOTT AF, ZAKI MSA, DALLAK MA, ALDERA H. Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling. Basic Res Cardiol. 2018;113:13. doi: 10.1007/s00395-018-0671-4. PubMed DOI

GONZALEZ A, SCHELBERT EB, DIEZ J, BUTLER J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71:1696–1706. doi: 10.1016/j.jacc.2018.02.021. PubMed DOI

GUO Y, DONG Z, SHI Y, WANG W, WANG L, SUN J, SUN X, TIAN Z, YAO J, LI Z, CHENG J, TIAN Y. Sonodynamic therapy inhibits fibrogenesis in rat cardiac fibroblasts induced by TGF-β1. Cell Physiol Biochem. 2016;40:579–588. doi: 10.1159/000452571. PubMed DOI

HEGER J, SCHIEGNITZ E, Von WALDTHAUSEN D, ANWAR MM, PIPER HM, EULER G. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol. 2010;224:120–126. doi: 10.1002/jcp.22102. PubMed DOI

KEMPF T, EDEN M, STRELAU J, NAGUIB M, WILLENBOCKEL C, TONGERS J, HEINEKE J, KOTLARZ D, XU J, MOLKENTIN JD, NIESSEN HW, DREXLER H, WOLLERT KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351–360. doi: 10.1161/01.RES.0000202805.73038.48. PubMed DOI

KEMPF T, WOLLERT KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin. 2009;5:537–547. doi: 10.1016/j.hfc.2009.04.006. PubMed DOI

KEMPF T, ZARBOCK A, WIDERA C, BUTZ S, STADTMANN A, ROSSAINT J, BOLOMINI-VITTORI M, KORF-KLINGEBIEL M, NAPP LC, HANSEN B, KANWISCHER A, BAVENDIEK U, BEUTEL G, HAPKE M, SAUER MG, LAUDANNA C, HOGG N, VESTWEBER D, WOLLERT KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17:581–588. doi: 10.1038/nm.2354. PubMed DOI

LACERDA-MIRANDA G, SOARES VM, VIERIA AK, LESSA JG, RODRIGUES-CUNHA AC, CORTEZ E, GARCIA-SOUZA EP, MOURA AS. Ghrelin signaling in heart remodeling of adult obese mice. Peptides. 2012;35:65–73. doi: 10.1016/j.peptides.2012.02.025. PubMed DOI

LAI CC, LIU CP, CHENG PW, LU PJ, HSIAO M, LU WH, SUN GC, LIOU JC, TSENG CJ. Paricalcitol attenuates cardiac fibrosis and expression of endothelial cell transition markers in isoproterenol-induced cardiomyopathic rats. Crit Care Med. 2016;44:e866–e874. doi: 10.1097/CCM.0000000000001736. PubMed DOI

LEWIS FC, KUMAR SD, ELLISON-HUGHES GM. Non-invasive strategies for stimulating endogenous repair and regenerative mechanisms in the damaged heart. Pharmacol Res. 2018;127:33–40. doi: 10.1016/j.phrs.2017.08.016. PubMed DOI

LILLENESS BM, FRISHMAN WH. Ghrelin and the cardiovascular system. Cardiol Rev. 2016;24:288–297. doi: 10.1097/CRD.0000000000000113. PubMed DOI

LIM E, LEE S, LI E, KIM Y, PARK S. Ghrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3β pathways. Exp Neurol. 2011;230:114–122. doi: 10.1016/j.expneurol.2011.04.003. PubMed DOI

LOK SI, WINKENS B, GOLDSCHMEDING R, Van GEFFEN AJ, NOUS FM, Van KUIK J, Van Der WEIDE P, KLOPPING C, KIRKELS JH, LAPHOR JR, DOVENDANS PA, De JONGE N, De WEGER RA. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14:1249–1256. doi: 10.1093/eurjhf/hfs120. PubMed DOI

LIN Y, MATSUMURA K, FUKUHARA M, KAGIYAMA S, FUJII K, IIDA M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension. 2004;43:977–982. doi: 10.1161/01.hyp.0000122803.91559.55. PubMed DOI

MAO Y, TOKUDOME T, KISHIMOTO I, OTANI K, NISHIMURA H, YAMAGUCHI O, OTSU K, MIYAZATO M, KANGAWA K. Endogenous ghrelin attenuates pressure overload-induced cardiac hypertrophy via a cholinergic anti-inflammatory pathway. Hypertension. 2015;65:1238–1244. doi: 10.1161/HYPERTENSIONAHA.114.04864. PubMed DOI

MAO Y, ZHANG S, YU F, LI H, GUO C, FAN X. Ghrelin attenuates liver fibrosis through regulation of TGF-β1 expression and autophagy. Int J Mol Sci. 2015;16:21911–21930. doi: 10.3390/ijms160921911. PubMed DOI PMC

MOHAMED SS, AHMED LA, ATTIA WA, KHATTAB MM. Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats. Biochem Pharmacol. 2015;98:403–411. doi: 10.1016/j.bcp.2015.10.004. PubMed DOI

MORINE KJ, QIAO X, YORK S, NATOV PS, PARUCHURI V, ZHANG Y, ARONOVITZ MJ, KARAS RH, KAPUR NK. Bone morphogenetic protein 9 reduces cardiac fibrosis and improves cardiac function in heart failure. Circulation. 2018;138:513–526. doi: 10.1161/CIRCULATIONAHA.117.031635. PubMed DOI PMC

NAGAYA N, MORIYA J, YASUMMURA Y, UEMATSU M, ONO F, SHIMIZU W, UENO K, KITAKAZE M, MIYATAKE K, KANGAWA K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–3679. doi: 10.1161/01.CIR.0000149746.62908.BB. PubMed DOI

NUAMNAICHATI N, SATO VH, MOONGKARNDI P, PARICHATIKANOND W, MANGMOOL S. Sustained β-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation. Life Sci. 2018;193:257–269. doi: 10.1016/j.lfs.2017.10.034. PubMed DOI

PEI XM, YUNG BY, YIP SP, YING M, BENZIE IF, SIU PM. Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway. Am J Physiol Endocrinol Metab. 2014;306:E311–E323. doi: 10.1152/ajpendo.00123.2013. PubMed DOI

PETER PS, BRADY JE, YAN L, CHEN W, ENGELHARDT S, WANG Y, SADOSHIMA J, VATNER SF, VATNER DE. Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest. 2007;117:1335–1343. doi: 10.1172/JCI29576. PubMed DOI PMC

POPELOVA A, KAKONOVÁ A, HRUBA L, KUNES J, MALETINSKA L, ŽELEZNA B. Potential neuroprotective and anti-apoptotic properties of a long-lasting stable analog of ghrelin: an in vitro study using SH-SY5Y cells. Physiol Res. 2018;67:339–346. doi: 10.33549/physiolres.933761. PubMed DOI

PRABBU SD, FRANGOGIANNIS NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119:91–112. doi: 10.1161/CIRCRESAHA.116.303577. PubMed DOI PMC

SANTHANAKRISHNAN R, CHONG JP, NG TP, LING LH, SIM D, LEONG KT, YEO PS, ONG HY, JAUFEERALLY F, WONG R, CHAI P, LOW AF, RICHARDS AM, LAM CS. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2012;14:1338–1347. doi: 10.1093/eurjhf/hfs130. PubMed DOI

SHAH AM, MANN DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378:704–712. doi: 10.1016/S0140-6736(11)60894-5. PubMed DOI PMC

SHIH YC, CHEN CL, ZHANG Y, MELLOR RL, KANTER EM, FANG Y, WANG HC, HUNG CT, NONG JY, CHEN HJ, LEE TH, TSENG YS, CHEN CN, WU CC, LIN SL, YAMADA KA, NERBONNE JM, YANG KC. Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating extracellular matrix protein folding and redox-sensitive cardiac fibroblast activation. Circ Res. 2018;122:1052–1068. doi: 10.1161/CIRCRESAHA.117.312130. PubMed DOI PMC

SHIRAI M, JOE N, TSUCHIMOCHI H, SONOBE T, SCHWENKE DO. Ghrelin supresses sympathetic hyperexcitation in acute heart failure in male rats: assessing centrally and peripherally mediated pathways. Endocrinology. 2015;156:3309–3316. doi: 10.1210/EN.2015-1333. PubMed DOI

SOEKI T, KISHIMOTO I, SCHWENKE DO, TOKUDOME T, HORIO T, YOSHIDA M, HOSODA H, KANGAWA K. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H426–H432. doi: 10.1152/ajpheart.00643.2007. PubMed DOI

SU SA, YANG D, WU Y, XIE Y, ZHU W, CAI Z, SHEN J, FU Z, WANG Y, JIA L, WANG Y, WANG JA, XIANG M. EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-β/Smad3 signaling. Circ Res. 2017;121:617–627. doi: 10.1161/CIRCRESAHA.117.311045. PubMed DOI

SUN GX, DING R, LI M, GUO Y, FAN LP, YUE LS, LI LY, ZHAO M. Ghrelin attenuates renal fibrosis and inflammation of obstructive nephropathy. J Urol. 2015;193:2107–2015. doi: 10.1016/j.juro.2014.11.098. PubMed DOI

TRAVERS JG, KAMAL FA, VALIENTE-ALANDI I, NIEMAN ML, SARGENT MA, LORENZ JN, MOLKENTIN JD, BLAXALL BC. Pharmacological and activated fibroblast targeting of Gβγ-GRK2 after myocardial ischemia attenuates heart failure progression. J Am Coll Cardiol. 2017;70:958–971. doi: 10.1016/j.jacc.2017.06.049. PubMed DOI PMC

VERGARO G, PRDU’HOMME M, FAZAL L, MERVAL R, PASSINO C, EMDIN M, SAMUEL JL, COHEN SOLAL A, DELCAYRE C. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 2016;67:606–612. doi: 10.1161/HYPERTENSIONAHA.115.06161. PubMed DOI

VERJANS R, PETERS T, BEAUMONT FJ, Van LEEUWEN R, Van HERWAARDEN T, VERHESEN W, MUNTS C, BIJNEN M, HENKENS M, DIEZ J, De WINDT LJ, Van NIEUWENHOVEN FA, Van BILSEN M, GOUMANS MJ, HEYMANS S, GONZALEZ A, SCHROEN B. MicroRNA-221/222 Family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 2018;71:280–288. doi: 10.1161/HYPERTENSIONAHA.117.10094. PubMed DOI

VIRDIS A, DURANTI E, COLUCCI R, IPPOLITO C, TIROTTA E, LORENZINI G, BERNARDINI N, BLANDIZZI C, TADDEI S. Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. Eur Heart J. 2015;36:3023–3030. doi: 10.1093/eurheartj/ehv365. PubMed DOI

VIRDIS A, LERMAN LO, REGOLI F, GHIADONI L, LERMAN A, TADDER S. Human ghrelin: a gastric hormone with cardiovascular properties. Curr Pharm Des. 2016;22:52–58. doi: 10.2174/1381612822666151119144458. PubMed DOI

WANG L, CHEN Q, LI G, KE D. Ghrelin ameliorates impaired angiogenesis of ischemic myocardium through GHSR1a-mediated AMPK/eNOS signal pathway in diabetic rats. Peptides. 2015;73:77–87. doi: 10.1016/j.peptides.2015.09.004. PubMed DOI

WANG L, CHEN Q, KE D, LI G. Ghrelin inhibits atherosclerotic plaque angiogenesis and promotes plaque stability in a rabbit atherosclerotic model. Peptides. 2017;90:17–26. doi: 10.1016/j.peptides.2017.01.013. PubMed DOI

WANG Q, SUI X, CHEN R, MA P, DING T, SUI D, YANG P. Anti-fibrotic actions of ghrelin by inhibition of the NADPH oxidase-ROS signaling pathway. Clin Exp Pharmacol Physiol. 2018;45:885. doi: 10.1111/1440-1681.12948. PubMed DOI

WANG S, SUN A, LI L, ZHAO G, JIA J, WANG K, GE J, ZOU Y. Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med. 2012;16:2301–2310. doi: 10.1111/j.1582-4934.2012.01538.x. PubMed DOI PMC

WOLLERT KC, KEMPF T. GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery? Eur J Heart Fail. 2012;14:1191–1193. doi: 10.1093/eurjhf/hfs158. PubMed DOI

XU X, DING F, PANG J, GAO X, XU RK, HAO W, CAO JM, CHEN C. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303:H703–H711. doi: 10.1152/ajpheart.00257.2011. PubMed DOI

XU XY, NIE Y, WANG FF, BAI Y, LV ZZ, ZHANG YY, LI ZJ, GAO W. Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation. J Biol Chem. 2014;289:10084–10094. doi: 10.1074/jbc.M113.516278. PubMed DOI PMC

YANG C, LIU J, LIU K, DU B, SHI K, DING M, LI B, YANG P. Ghrelin suppresses cardiac fibrosis of post-myocardial infarction heart failure rats by adjusting the activin A-follistatin imbalance. Peptides. 2018;99:27–35. doi: 10.1016/j.peptides.2017.10.018. PubMed DOI

YIN Q, LU H, BAI Y, TIAN A, YANG Q, WU J, YANG C, FAN TP, ZHANG Y, ZHENG X, ZHENG X, LI Z. A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway. Br J Pharmacol. 2015;172:5573–5585. doi: 10.1111/bph.13133. PubMed DOI PMC

YING C, LIU T, LING H, CHENG M, ZHOU X, WANG S, MAO Y, CHEN L, ZHANG R, LI W. Glucose variability aggravates cardiac fibrosis by altering AKT signalling path. Diab Vasc Dis Res. 2017;14:327–335. doi: 10.1177/1479164117698917. PubMed DOI

ZHANG W, CHANCEY AL, TZENG HP, ZHOU Z, LAVINE KJ, GAO F, SIVASUBRAMANIAN N, BARGER PM, MANN DL. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation. 2011;124:2106–2116. doi: 10.1161/CIRCULATIONAHA.111.052399. PubMed DOI PMC